Rhythm Pharmaceuticals Inc’s recently made public that its Chief Human Resources Officer Cramer Pamela J. unloaded Company’s shares for reported $0.13 million on Jul 29 ’25. In the deal valued at $85.93 per share,1,520 shares were sold. As a result of this transaction, Cramer Pamela J. now holds 20,814 shares worth roughly $1.88 million.
Then, Smith Hunter C sold 42,120 shares, generating $3,389,756 in total proceeds. Upon selling the shares at $80.48, the Chief Financial Officer now owns 116,915 shares.
Before that, Shulman Joseph sold 7,969 shares. Rhythm Pharmaceuticals Inc shares valued at $619,851 were divested by the Chief Technical Officer at a price of $77.78 per share. As a result of the transaction, Shulman Joseph now holds 8,509 shares, worth roughly $0.77 million.
Goldman initiated its Rhythm Pharmaceuticals Inc [RYTM] rating to a Buy in a research note published on July 10, 2025; the price target was $97. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in early July with a ‘”an Outperform”‘ rating. BofA Securities also remained covering RYTM and has increased its forecast on April 07, 2025 with a “Buy” recommendation from previously “Neutral” rating.
Price Performance Review of RYTM
On Monday, Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] saw its stock jump 2.20% to $90.24. Over the last five days, the stock has gained 5.32%. Rhythm Pharmaceuticals Inc shares have risen nearly 87.18% since the year began. Nevertheless, the stocks have risen 61.20% over the past one year.
How much short interest is there in Rhythm Pharmaceuticals Inc?
A steep rise in short interest was recorded in Rhythm Pharmaceuticals Inc stocks on 2025-07-15, growing by 32000.0 shares to a total of 4.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 4.76 million shares. There was a rise of 0.67%, which implies that there is a positive sentiment for the stock.
